SLC18A2 and thanatophoric dysplasia: More recently, there is growing evidence that the vesicular monoamine transporter 2 (VMAT2/SLC18A2) gene may be associated with TD, including association findings from genetic studies (Tsai et al., 2010; Zai et al., 2013) and promising findings from clinical trials on the VMAT2 inhibitors deutetrabenazine and valbenazine as treatment for TD (Anderson et al., 2017; Factor et al., 2017; Fernandez et al., 2017; Hauser et al., 2017).